Document is current

Article History

Received: 24 January 2025

Accepted: 24 April 2025

First Online: 23 July 2025

Declarations

:

: The study adhered to the guidelines outlined in the Declaration of Helsinki and conformed to the Good Epidemiological Practices as defined by the International Society for Pharmacoeconomics and Outcomes Research’s. The study received ethics approval from Chang Gung Memorial Hospital Institutional Review Board (IRB number: 202001354B0). Due to enrolment challenges the study was extended through the IRB approval process four times (IRB no. 202001354B0C601/ IRB no. 202001354B0C501/ IRB no. 202001354B0C502/ IRB no. 202001354B0C602). Informed consent was obtained from the study population and respondents had the right to withdraw at any time from the study.

: Not applicable.

: CC and LW are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and shareholders of Merck & Co., Inc., Rahway, NJ, USA, which funded the study. Merck & Co., Inc., Rahway, NJ, USA is the manufacturer of a rotavirus vaccine (RotaTeqTM). Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA sponsored the study and contracted Oracle Life Sciences, Taiwan, and Cerner Enviza, China. JV and MH received consulting fees from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.Oracle Life Sciences, Taiwan and Cerner Enviza, China, received funding from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA to conduct the study. QL and JL are employees of Oracle Life Sciences, Taiwan, and FQ is an employee of Cerner Enviza, China.